• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primary

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    s41467-024-47195-7.pdf
    Size:
    2.029Mb
    Format:
    PDF
    Description:
    Found with Open Access Button
    Download
    Authors
    Conway, Alicia M
    Pearce, Simon P
    Clipson, Alexandra
    Hill, Steven M
    Chemi, Francesca
    Slane-Tan, Dan
    Ferdous, Seba
    Hossain, A S Mukarram
    Kamieniecka, Katarzyna
    White, Daniel J
    Mitchell, Claire
    Kerr, Alastair
    Krebs, Matthew G
    Brady, Gerard
    Dive, Caroline
    Cook, Natalie
    Rothwell, Dominic G
    Show allShow less
    Affiliation
    Nucleic Acid Biomarker Team, Cancer Research UK National Biomarker Centre, The University of Manchester, Manchester, UK. Division of Cancer Sciences, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK. Bioinformatics and Biostatistics Team, Cancer Research UK National Biomarker Centre, The University of Manchester, Manchester, UK. Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.
    Issue Date
    2024
    
    Metadata
    Show full item record
    Abstract
    Cancers of Unknown Primary (CUP) remains a diagnostic and therapeutic challenge due to biological heterogeneity and poor responses to standard chemotherapy. Predicting tissue-of-origin (TOO) molecularly could help refine this diagnosis, with tissue acquisition barriers mitigated via liquid biopsies. However, TOO liquid biopsies are unexplored in CUP cohorts. Here we describe CUPiD, a machine learning classifier for accurate TOO predictions across 29 tumour classes using circulating cell-free DNA (cfDNA) methylation patterns. We tested CUPiD on 143 cfDNA samples from patients with 13 cancer types alongside 27 non-cancer controls, with overall sensitivity of 84.6% and TOO accuracy of 96.8%. In an additional cohort of 41 patients with CUP CUPiD predictions were made in 32/41 (78.0%) cases, with 88.5% of the predictions clinically consistent with a subsequent or suspected primary tumour diagnosis, when available (23/26 patients). Combining CUPiD with cfDNA mutation data demonstrated potential diagnosis re-classification and/or treatment change in this hard-to-treat cancer group.
    Citation
    Conway AM, Pearce SP, Clipson A, Hill SM, Chemi F, Slane-Tan D, et al. A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primary. Nature communications. 2024 Apr 17;15(1):3292. PubMed PMID: 38632274. Pubmed Central PMCID: PMC11024142 Bioven, Amgen, Carrick Therapeutics, Merck AG, Taiho Oncology, GSK, Bayer, Boehringer Ingelheim, Roche, BMS, Novartis, Celgene, Epigene Therapeutics Inc, Angle PLC, Menarini, Clearbridge Biomedics, Thermo Fisher Scientific, Neomed Therapeutics. C.D. has received/receives honoraria/consultancy fees from Biocartis, Merck, AstraZeneca and GRAIL. Outside of the scope of work, research funding/educational research grants has been received from by the Experimental Cancer Medicine Team (PI: Cook) from AstraZeneca, Bayer, Pfizer, Orion, Taiho, Oncology, Roche, Starpharma, Eisai, RedX, UCB, Boeringher, Merck, Stemline Tarveda and Avacta. M.G.K has received consultancy/advisory board fees from Bayer, Guaradant Health, Janssen, Roche, Seattle Genetics; speakers fees from Janssen, Roche; research funding from Novartis, Roche and travel expenses from Immutep, Janseen and Roche. The remaining authors declare no competing interests. Epub 2024/04/18. eng.
    Journal
    Nature Communications
    URI
    http://hdl.handle.net/10541/627005
    DOI
    10.1038/s41467-024-47195-7
    PubMed ID
    38632274
    Additional Links
    https://dx.doi.org/10.1038/s41467-024-47195-7
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1038/s41467-024-47195-7
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • A Fast, Affordable, and Minimally Invasive Diagnostic Test for Cancer of Unknown Primary Using DNA Methylation Profiling.
    • Authors: De Wilde J, Van Paemel R, De Koker A, Roelandt S, Van de Velde S, Callewaert N, Van Dorpe J, Creytens D, De Wilde B, De Preter K
    • Issue date: 2024 Aug
    • Leveraging locus-specific epigenetic heterogeneity to improve the performance of blood-based DNA methylation biomarkers.
    • Authors: Miller BF, Pisanic Ii TR, Margolin G, Petrykowska HM, Athamanolap P, Goncearenco A, Osei-Tutu A, Annunziata CM, Wang TH, Elnitski L
    • Issue date: 2020 Oct 20
    • Liquid Biopsy of Methylation Biomarkers in Cell-Free DNA.
    • Authors: Luo H, Wei W, Ye Z, Zheng J, Xu RH
    • Issue date: 2021 May
    • A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples.
    • Authors: Gallardo-Gómez M, Moran S, Páez de la Cadena M, Martínez-Zorzano VS, Rodríguez-Berrocal FJ, Rodríguez-Girondo M, Esteller M, Cubiella J, Bujanda L, Castells A, Balaguer F, Jover R, De Chiara L
    • Issue date: 2018
    • Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary.
    • Authors: Kato S, Weipert C, Gumas S, Okamura R, Lee S, Sicklick JK, Saam J, Kurzrock R
    • Issue date: 2021
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.